Concepedia

Ken Kato

KK

3

Publications

115

Citations

3

H-Index

2022

Active since

Affiliations

Tokyo National Hospital(Current)

BeiGene (China)

Ken Kato is an author at Tokyo National Hospital specializing in medicine, pathology, and oncology.

Top concepts

Publications per year

2022–2024

3

Publications

3

Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Markus Moehler, Ken Kato, Hendrik‐Tobias Arkenau et al. · Journal of Clinical Oncology · 2023 · 76 citations

, , +22

LBA-1 RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)

Hyun-Woo Yoon, Ken Kato, Eric Raymond et al. · Annals of Oncology · 2022 · 28 citations

First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC).

Scott Kopetz, Valentina Boni, Ken Kato et al. · Journal of Clinical Oncology · 2024 · 11 citations

Rows per page

1–3 of 3